Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2mutation carriers
Antonis C. Antoniou(Weatherford College), Rosalind A. Eeles(Royal Marsden NHS Foundation Trust), Juul Wijnen(Memorial University of Newfoundland), Karoline Kuchenbaecker(University of Cambridge), Richard Rosenquist(Karolinska University Hospital), Annika Lindblom(Karolinska University Hospital), Jan Lubiński(Tumour Institute of Tuscany), Mieke Kriege, Marjolijn J. L. Ligtenberg(Radboud University Nijmegen), Elżbieta Złowowcka-Perłowska(Pomeranian Medical University), Katja Harbst(Lund University), Ana Osório(Spanish National Cancer Research Centre), Margreet G.E.M. Ausems(McGill University Health Centre), Daniel Barrowdale(University of Cambridge), Javier Benı́tez(Spanish National Cancer Research Centre), Anna Jakubowska(Pomeranian Medical University), Susan M. Domchek(University City Science Center), Ute Hamann(German Cancer Research Center), Hanne Meijers‐Heijboer(German Cancer Research Center), D. Gareth Evans(Manchester Academic Health Science Centre), M. Durán(Universidad de Valladolid), Per Karlsson(University of Gothenburg), Andrew Lee(University of Cambridge), Raquel Andrés(Unknown), Chris Jacobs(Guy's and St Thomas' NHS Foundation Trust), Theo A. van Os(Amsterdam UMC Location University of Amsterdam), Brita Arver(Karolinska University Hospital), Frans B.L. Hogervorst(The Netherlands Cancer Institute), Katarzyna Jaworska(International Hereditary Cancer Center), Katarzyna Durda(Pomeranian Medical University), Tim Rebbeck(University of Pennsylvania), Lesley McGuffog(University of Cambridge), Jan C. Oosterwijk(University Medical Center Groningen), Sue Healey(QIMR Berghofer Medical Research Institute), J. Margriet Collée(Erasmus MC Cancer Institute), Radka Platte(University of Cambridge), Steve D. Ellis(University of Cambridge), Niklas Loman(Lund University), Penny Soucy(University of Cambridge), Senno Verhoef(The Netherlands Cancer Institute), Susan Peock(Cancer Research UK), Elena Fineberg, Fiona Lalloo(Manchester Academic Health Science Centre), Olga M. Sinilnikova(Hospices Civils de Lyon), Jonathan Beesley(QIMR Berghofer Medical Research Institute), Maria A. Caligo(Azienda Ospedaliera Universitaria Pisana), Debra Frost(University of Cambridge), E. Gómez(Maastricht University Medical Centre)
Cited by 96
Related Papers
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k